Fidel Makapugay
Family Medicine · Collierville, TNNPI 1447200464
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 149 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,090 and has fallen 95.2% since, to $52 in 2023.
Across 149 payments — averaging $14.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$448
- Lilly USA, LLC$336
- Novo Nordisk$223
- Takeda Pharmaceuticals U.S.A., Inc.$214
- AbbVie$108
- Pfizer$100
- plus $751 from 15 others
What the payments were for
- Food & beverage$2,172100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 27 | $448 |
| Lilly USA, LLC | 35 | $336 |
| Novo Nordisk | 14 | $223 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $214 |
| AbbVie(2 entities) | 8 | $108 |
| Pfizer | 7 | $100 |
| Kowa Pharmaceuticals America, Inc. | 6 | $88 |
| Johnson & Johnson | 4 | $74 |
| Nalpropion Pharmaceuticals LLC | 6 | $69 |
| Astellas Pharma US Inc | 5 | $66 |
| Boehringer Ingelheim | 4 | $66 |
| Arbor Pharmaceuticals, Inc. | 4 | $60 |
| Optinose US, Inc. | 3 | $55 |
| GSK | 4 | $55 |
| Merck | 4 | $50 |
| Shire North American Group Inc | 3 | $47 |
| Genentech USA, Inc. | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $26 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Antares Pharma, Inc. | 1 | $17 |
| Amgen | 1 | $16 |
How this compares
$2,180 in reported general payments places this provider in the 70th percentile of 2,087 family medicine providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 51 | $640 |
| Losartan Potassium | 42 | $522 |
| Omeprazole | 42 | $513 |
| Atorvastatin Calcium | 47 | $490 |
| Metoprolol Succinate | 23 | $467 |
| Finasteride | 14 | $334 |
| Simvastatin | 38 | $307 |
| Amlodipine Besylate | 52 | $304 |
| Lisinopril | 46 | $301 |
| Tamsulosin Hcl | 24 | $296 |
| ClopidogrelClopidogrel Bisulfate | 14 | $278 |
| Levothyroxine Sodium | 31 | $264 |
| Ezetimibe | 11 | $234 |
| Gabapentin | 13 | $233 |
| Metformin Hcl | 41 | $228 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Collierville
- Kevin DennisFranklin$354K
- Charolette JacksonBartlett$162K
- Keren HolmesNashville$58K
- Kabir Harricharan SinghNewport$49K
- Khaisha GistAntioch$49K
- Jerry PunchKnoxville$45K
- Christopher HollowayAntioch$41K
- Curtis JantziKingsport$39K
- Ellen ClelandChattanooga$38K
- Meredith SchweitzerAntioch$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.